NASDAQ:CBIO Catalyst Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.78 -0.01 (-0.56%) (As of 07/5/2022 02:50 PM ET) Add Compare Share Today's Range$1.74▼$1.8150-Day Range$0.36▼$1.7952-Week Range$0.35▼$5.20Volume10,044 shsAverage Volume2.73 million shsMarket Capitalization$56.03 millionP/E RatioN/ADividend YieldN/APrice Target$13.33 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Catalyst Biosciences MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside653.3% Upside$13.33 Price TargetShort InterestHealthy6.27% of Float Sold ShortDividend StrengthN/ASustainability-0.38Upright™ Environmental ScoreNews Sentiment0.83Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.24) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.09 out of 5 starsMedical Sector388th out of 1,428 stocksPharmaceutical Preparations Industry181st out of 680 stocks 3.2 Analyst's Opinion Consensus RatingCatalyst Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.33, Catalyst Biosciences has a forecasted upside of 653.3% from its current price of $1.77.Amount of Analyst CoverageCatalyst Biosciences has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted6.27% of the float of Catalyst Biosciences has been sold short.Short Interest Ratio / Days to CoverCatalyst Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Catalyst Biosciences has recently decreased by 42.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Biosciences does not currently pay a dividend.Dividend GrowthCatalyst Biosciences does not have a long track record of dividend growth. Previous Next 3.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Biosciences has received a 52.72% net impact score from Upright. Catalyst Biosciences seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is driven by its "Preclinical research services for physical health" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Biosciences is -0.38. Previous Next 2.7 News and Social Media Coverage News SentimentCatalyst Biosciences has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Catalyst Biosciences this week, compared to 0 articles on an average week.Search Interest15 people have searched for CBIO on MarketBeat in the last 30 days. This is an increase of 88% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.92% of the stock of Catalyst Biosciences is held by insiders.Percentage Held by Institutions62.37% of the stock of Catalyst Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Catalyst Biosciences are expected to grow in the coming year, from ($1.24) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Biosciences is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Biosciences is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCatalyst Biosciences has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Catalyst Biosciences (NASDAQ:CBIO) StockCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.Read More CBIO Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comCatalyst Biosciences, Inc. (NASDAQ:CBIO) Short Interest UpdateJune 29, 2022 | seekingalpha.comCatalyst Biosciences plans to distribute $65M cash to stockholdersJune 29, 2022 | marketwatch.comCatalyst Biosciences Shares Jump Premarket on Plans to Distribute Cash >CBIOJune 29, 2022 | finance.yahoo.comCatalyst Biosciences Announces Plan to Distribute Cash to StockholdersJune 28, 2022 | americanbankingnews.comCatalyst Biosciences (NASDAQ:CBIO) Stock Passes Above 200 Day Moving Average of $0.78June 21, 2022 | americanbankingnews.comAgeX Therapeutics (NYSE:AGE) and Catalyst Biosciences (NASDAQ:CBIO) Critical ComparisonMay 26, 2022 | finance.yahoo.comThe Petri Dish: NIH gives $68M to Pfizer-partnered AI startupMay 23, 2022 | uk.investing.comWhy Catalyst Biosciences Shares Are Skyrocketing TodayMay 23, 2022 | marketwatch.comCatalyst Biosciences Shares Soar After Complement Portfolio Sale >CBIOMay 23, 2022 | investorplace.comWhy Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?May 9, 2022 | benzinga.comRecap: Catalyst Biosciences Q1 EarningsMay 9, 2022 | finance.yahoo.comCatalyst Biosciences Reports First Quarter 2022 Operating & Financial ResultsApril 8, 2022 | finance.yahoo.comHere's Why Catalyst Biosciences (NASDAQ:CBIO) Must Use Its Cash WiselyMarch 31, 2022 | seekingalpha.comCatalyst Biosciences GAAP EPS of -$2.87 misses by $0.01, revenue of $7.34M beats by $2.19MMarch 31, 2022 | finance.yahoo.comCatalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate UpdateMarch 16, 2022 | seekingalpha.comBiogen ends partnership with Catalyst Biosciences for eye disease candidateMarch 15, 2022 | finance.yahoo.comCatalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO’s Complement Portfolio in OphthalmologyFebruary 17, 2022 | marketwatch.comCatalyst Biosciences Hires Adviser to Explore Strategic Options >CBIOFebruary 17, 2022 | finance.yahoo.comCatalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic AlternativesJanuary 25, 2022 | seekingalpha.comCatalyst Bio's stock jumps 21% after securing Rare Pediatric Disease tag for CB 4332January 25, 2022 | finance.yahoo.comCatalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI DeficiencyJanuary 12, 2022 | finance.yahoo.comCatalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should KnowJanuary 11, 2022 | nasdaq.comCatalyst Biosciences Inc Shares Fall 5.2% Below Previous 52-Week Low - Market MoverJanuary 9, 2022 | nasdaq.comCatalyst Biosciences Inc Shares Close in on 52-Week Low - Market MoverJanuary 5, 2022 | nasdaq.comA Catalyst Biosciences, Inc. (NASDAQ:CBIO) insider lowered their holding by 10% earlier this yearSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:CBIO CUSIP87611R30 CIK1124105 Webwww.catalystbiosciences.com Phone(650) 871-0761Fax336-480-2107Employees56Year Founded2003Company Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$13.33 High Stock Price Forecast$18.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+649.1%Consensus RatingHold Rating Score (0-4)2.33333333333333 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,930,000.00 Net Margins-1,200.77% Pretax Margin-1,200.77% Return on Equity-149.54% Return on Assets-115.88% Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.78 Sales & Book Value Annual Sales$7.34 million Price / Sales7.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book1.36Miscellaneous Outstanding Shares31,480,000Free Float30,558,000Market Cap$56.03 million OptionableOptionable Beta1.51 Social Links Catalyst Biosciences Frequently Asked Questions Should I buy or sell Catalyst Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Biosciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Catalyst Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBIO, but not buy additional shares or sell existing shares. View analyst ratings for Catalyst Biosciences or view top-rated stocks. What is Catalyst Biosciences' stock price forecast for 2022? 3 Wall Street research analysts have issued 12 month price targets for Catalyst Biosciences' shares. Their CBIO stock forecasts range from $4.00 to $18.00. On average, they expect Catalyst Biosciences' stock price to reach $13.33 in the next year. This suggests a possible upside of 653.3% from the stock's current price. View analysts' price targets for Catalyst Biosciences or view top-rated stocks among Wall Street analysts. How has Catalyst Biosciences' stock performed in 2022? Catalyst Biosciences' stock was trading at $0.9140 on January 1st, 2022. Since then, CBIO shares have increased by 93.7% and is now trading at $1.77. View the best growth stocks for 2022 here. When is Catalyst Biosciences' next earnings date? Catalyst Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Catalyst Biosciences. How were Catalyst Biosciences' earnings last quarter? Catalyst Biosciences, Inc. (NASDAQ:CBIO) issued its quarterly earnings results on Monday, May, 9th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.10. The biopharmaceutical company earned $0.79 million during the quarter. Catalyst Biosciences had a negative trailing twelve-month return on equity of 149.54% and a negative net margin of 1,200.77%. View Catalyst Biosciences' earnings history. When did Catalyst Biosciences' stock split? How did Catalyst Biosciences' stock split work? Catalyst Biosciences shares reverse split before market open on Monday, February 13th 2017. The 1-15 reverse split was announced on Friday, February 10th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 10th 2017. An investor that had 100 shares of Catalyst Biosciences stock prior to the reverse split would have 7 shares after the split. Who are Catalyst Biosciences' key executives? Catalyst Biosciences' management team includes the following people: Dr. Nassim Usman Ph.D., Pres, CEO & Director (Age 62, Pay $613.11k)Ms. Seline E. Miller CPA, Sr. VP of Fin., Interim Chief Financial & Principal Accounting OfficerDr. Grant Blouse M.Sc., Ph.D., Chief Scientific OfficerDr. Howard Levy M.B.B.Ch., M.M.M., Ph.D., Consultant (Age 68, Pay $434.21k)Ms. Ana Kapor, Sr. Director of Investor Relations & Corp. CommunicationsDr. Tom Knudsen D.V.M., Ph.D., Sr. VP of Corp. Devel. Who are some of Catalyst Biosciences' key competitors? Some companies that are related to Catalyst Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO). View all of CBIO's competitors. What other stocks do shareholders of Catalyst Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Biosciences investors own include Baozun (BZUN), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO), Amarin (AMRN), ImmunoGen (IMGN), Sarepta Therapeutics (SRPT), VBI Vaccines (VBIV), Biocept (BIOC) and Celsion (CLSN). What is Catalyst Biosciences' stock symbol? Catalyst Biosciences trades on the NASDAQ under the ticker symbol "CBIO." How do I buy shares of Catalyst Biosciences? Shares of CBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Catalyst Biosciences' stock price today? One share of CBIO stock can currently be purchased for approximately $1.77. How much money does Catalyst Biosciences make? Catalyst Biosciences (NASDAQ:CBIO) has a market capitalization of $55.72 million and generates $7.34 million in revenue each year. The biopharmaceutical company earns $-87,930,000.00 in net income (profit) each year or ($2.54) on an earnings per share basis. How many employees does Catalyst Biosciences have? Catalyst Biosciences employs 56 workers across the globe. When was Catalyst Biosciences founded? Catalyst Biosciences was founded in 2003. How can I contact Catalyst Biosciences? Catalyst Biosciences' mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The official website for Catalyst Biosciences is www.catalystbiosciences.com. The biopharmaceutical company can be reached via phone at (650) 871-0761, via email at investors@catbio.com, or via fax at 336-480-2107. This page (NASDAQ:CBIO) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
